POP-OUT | CLOSE
 
 
3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine
 
VGH is found in 7 entries
VGH
  •   Chemical Component Summary   Hide
    Name 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine
    Identifiers 3-[(1R)-1-(2,6-dichloro-3-fluoro-phenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
    Synonyms CRIZOTINIB
    Formula C21 H22 Cl2 F N5 O
    Molecular Weight 450.34 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key KTEIFNKAUNYNJU-GFCCVEGCSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB08865   (Stereoisomeric match)
    Name Crizotinib
    Groups approved
    Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
    Synonyms
    • (R)-Crizotinib
    • C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
    • C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
    • Crizotinibum
    • MET Tyrosine Kinase Inhibitor PF-02341066
    • PF 2341066
    • PF-2341066
    [more]
    Brand names Xalkori
    Affected organism Humans and other mammals
    Indication Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
    Mechanism of action Crizotinib is a tyrosine kinase receptor inhibitor. More specifically, it inhibits anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteur d'Origine Nantais (RON). Abnormalities in the ALK gene caused by mutations or translocations may lead to expression of oncogenic fusion proteins. In patients with NSCLC, they have the EML4-ALK gene. Crizotinib inhibits ALK tyrosine kinase which ultimately results in decreased proliferation of cells that carry the genetic mutation and tumour survivability.
    Route of administration Oral
    Categories Protein Kinase Inhibitors
    ATC-Code L01XE16
    AHFS-Code 10:00
    CAS number 877399-52-5
    Targets
    Name Sequence search Pharmacological action Actions
    ALK tyrosine kinase receptor   Search  yes inhibitor
    Hepatocyte growth factor receptor   Search  yes inhibitor
     
Ligand Image